SOURCE: Arrayit Corporation

Arrayit Corporation

October 05, 2009 07:00 ET

Arrayit Deploys Next-Generation Proteomics Platform

Patented Technology Offers Breakthrough for Multivariate Molecular Diagnostics

SUNNYVALE, CA--(Marketwire - October 5, 2009) - Arrayit Corporation (OTCBB: ARYC), a life sciences and health care technology innovator, announces that on October 1st, 2009, the company deployed its next-generation proteomics platform to customers working in the areas of proteomics and in vitro molecular diagnostics.

Arrayit's new proteomics platform provides a patented and comprehensive instrumentation, software and consumables solution for peptide microarray analysis. Peptides are synthetic versions of proteins, the body's ultimate information messengers that carry out instructions encoded by the genes in the human genome. Peptide microarrays allow scientists and doctors to explore the protein world with pinpoint precision.

"We are pleased at the rate of technological innovation taking place in our laboratories," states Rene Schena, CEO and co-founder of Arrayit Corp. "Our next-generation proteomics tools are complimentary to advances in solid phase DNA sequencing, opening up exciting new frontiers in basic research and diagnostics."

About Arrayit Corporation

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit for more information.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that constitute forward-looking statements are based on currently available information, involve certain risks and uncertainties and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. Risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K/A for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2009 and Form 10-Q/A for the fiscal third quarter ended September 30, 2008.

Contact Information